United States-based AbbVie (NYSE: ABBV) announced on Monday that it has submitted an application to the United States Food and Drug Administration (FDA) requiring approval for risankizumab-rzaa (600mg intravenous (IV) induction and 360mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor to treat patients 16 years and older with moderate to severe Crohn's disease.
The submission is based on the safety and efficacy data from three Phase three studies, ADVANCE, MOTIVATE and FORTIFY. The safety profile of all tested doses of the product in moderate to severe Crohn's disease in the ADVANCE, MOTIVATE and FORTIFY studies was consistent with the safety profile of risankizumab-rzaa.
The ADVANCE and MOTIVATE studies are Phase three multicentre, randomised, double-blind, placebo-controlled induction studies aimed at assessing the efficacy and safety of two doses of risankizumab-rzaa, 600mg and 1200mg, in adults with moderate to severe Crohn's disease, compared to placebo.
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use